Lung Cancer
Volume 66, Issue 3 , Pages 327-332 , December 2009

Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer

  • Silvia Novello

      Affiliations

    • Department of Clinical & Biological Sciences, Thoracic Oncology Unit, University of Turin, Italy
    • Corresponding Author InformationCorresponding author at: University of Torino, Department of Clinical & Biological Sciences, Thoracic Oncology Unit, S. Luigi Hospital - Regione Gonzole 10, 10043 Orbassano (Torino), Italy. Tel.: +39 011 9026978; fax: +39 011 9038616.
    • ,
  • Alfredo Falcone

      Affiliations

    • Medical Oncology, Livorno, Italy
    • ,
  • Lucio Crinò

      Affiliations

    • Medical Oncology, Monteluce Hospital, Perugia, Italy
    • ,
  • Massimo Rinaldi

      Affiliations

    • Medical Oncology Division B, IRCCS Regina Hospital, Rome, Italy
    • ,
  • Mario Nardi

      Affiliations

    • Medical Oncology “Bianchi-Melacrino Morelli” Hospital, Reggio, Calabria, Italy
    • ,
  • Filippo De Marinis

      Affiliations

    • Thoracic Oncology Unit, San Camillo Forlanini Hospital, Rome, Italy
    • ,
  • Maurizio Tonato

      Affiliations

    • Medical Oncology, Monteluce Hospital, Perugia, Italy
    • ,
  • Carmelo Tibaldi

      Affiliations

    • Medical Oncology, Livorno, Italy
    • ,
  • Angelo Tinazzi

      Affiliations

    • SENDO Foundation, Milano, Italy
    • ,
  • Francesca Russo

      Affiliations

    • Medical Department, Eli Lilly Italy, Florence, Italy
    • ,
  • Nicoletta Grassivaro

      Affiliations

    • Medical Department, Sanofi Aventis, Milano, Italy
    • ,
  • Giorgio Vittorio Scagliotti

      Affiliations

    • Department of Clinical & Biological Sciences, Thoracic Oncology Unit, University of Turin, Italy

Received 7 October 2008 ,Revised 22 January 2009 ,Accepted 15 February 2009.

References 

  1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:889–90.
  2. Hoang T, Traynor AM, Schiller JH. Chemotherapy for advanced non-small cell lung cancer. In:  Pass HI,  Carbone DP,  Johnson DH,  Minna JD,  Turrisi AT editor. Lung cancer: principles and practice. 3rd ed.. Lippincott Williams & Wilkins; 2005;p. 571–587
  3. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2000;357:1478–1484
  4. Kosmidis PA, Kalofonos HP, Christodoulou C, et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer: a phase III study of the Hellenic Cooperative Oncology Group. Ann. Oncol. 2008;19:115–122
  5. D’Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. 2005;23:2926–2936
  6. Patel R, Keiser LW, Justice GR, et al. ACORN 9901: a multicenter randomised trial of docetaxel+gemcitabine versus weekly paclitaxel+gemcitabine in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 2002;21:320a;(abstract 1276)
  7. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 2004;22:330–353
  8. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr. Treat. Options Oncol. 2007;8:38–46
  9. Smith TJ, Khatcheressian J, Lyman GH, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 2006;24:3187–3205
  10. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat. Rep. 1985;69:1375–1381
  11. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 2002;20:4285–4291
  12. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol. 2005;23:2937–2945
  13. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann. Oncol. 2005;16:602–610
  14. Rothenberg ML, Sharma A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann. Oncol. 1998;9:733–738
  15. Sternberg CN, Calabrò F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993–2998
  16. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J. Clin. Oncol. 2003;21:2004–2010
  17. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J. Clin. Oncol. 2008;26:5755–5760
  18. Edelman MJ, Clark JI, Chansky K, et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin. Cancer Res. 2004;10:5022–5026
  19. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2009;27:591–598

PII: S0169-5002(09)00107-X

doi: 10.1016/j.lungcan.2009.02.009

Lung Cancer
Volume 66, Issue 3 , Pages 327-332 , December 2009

Article Tools

* Image Usage & Resolution